In patients with psoriatic arthritis, the use of anti-TNF-α was associatedwith reduced risk of developing DM (OR = 0.62) compared with the use of otherdisease modifying drugs (except methotrexate). This evidence concerns the gene TNF and psoriatic arthritis.